The American biotechnology firm Amgen has signed a memorandum of understanding with the Algerian Ministry of Health to bolster prevention efforts against cardiovascular diseases, the leading cause of death in the country, accounting for 34% of fatalities. Yasmine Ait Yahia, General Manager of Amgen Algeria, stated that the agreement reflects a shared commitment to patient health and awareness regarding cardiovascular risk factors. This partnership supports the Algerian government’s ongoing initiatives to modernize healthcare facilities and improve access to medical treatments across the nation.